Adenosylmethionine succinate, a new heavy-duty drug of Zhenyuan, Zhejiang Province, is expected to obtain production approval this month

According to the website of the State Food and Drug Administration (CFDA) on July 2, the state of adenosylmethionine for raw materials and preparations for injection of adenosylmethionine, a new hepatobiliary drug declared and produced by Zhenyuan, Zhejiang Province, has changed to "approved - to be certified" The company is expected to obtain the production approval document and reap the heavyweight varieties around this month According to the official website of Zhenyuan pharmaceutical, a subsidiary of Zhenyuan, Zhejiang Province, ademetionine succinate was developed by the company in 2004 If it is approved to be listed, it is likely to become a major new strategic product Zhejiang Zhenyuan insiders have said that the product will obtain production approval in the near future The data show that ademetionine is mainly suitable for intrahepatic cholestasis and intrahepatic cholestasis in pregnancy before and after cirrhosis, which can make the abnormal liver function turn to normal It is reported that in 2013, the sales revenue of ademetionine succinate injection of Haizheng pharmaceutical, the first pharmaceutical imitator, reached 167 million yuan, accounting for more than one third of the market.